This is consistent with previously reported preclinical prostate cancer studies of KLK2 distribution (14, 20), highlighting KLK2 as potentially low-risk for on-target, off-tumor toxicity because of its high specificity to prostate and prostate-derived tumors, with minimal-to-no expression in other normal tissues. The gene discussed is KLK2; the disease is neoplasm.